U.S. Pharma Stock News

In early March 2026, Texas Instruments announced a collaboration with NVIDIA to combine its real-time motor control, sensing, radar and power technologies with NVIDIA’s robotics compute and simulation platforms, aiming to accelerate safer real-world deployment of humanoid robots and showcasing a radar–camera sensor fusion demo at NVIDIA GTC in San Jose. A key innovation is TI’s mmWave radar-based sensor fusion with NVIDIA Jetson Thor, designed to deliver low-latency 3D perception and...

Centuri Holdings (CTRI) has just combined a turnaround earnings report with fresh 2026 revenue guidance, shifting from a full year net loss to net income and setting expectations for US$3.24b to US$3.54b in sales. See our latest analysis for Centuri Holdings. At a share price of US$30.01, Centuri’s recent earnings turnaround and 2026 revenue outlook sit against a 1-year total shareholder return of 78.10%, with a 90-day share price return of 16.82%. This suggests momentum has been building...

Ventas (VTR) continues to attract attention from income focused investors, with its S&P 500 real estate investment trust profile and exposure to senior housing and healthcare facilities across North America and the United Kingdom. See our latest analysis for Ventas. At a share price of $86.21, Ventas has posted an 11.48% year to date share price return, alongside a 31.29% total shareholder return over one year and a 112.30% total shareholder return over three years, which indicates momentum...

Cadre Holdings, Inc. has scheduled the release of its Q4 2025 results for after the market close on March 10, 2026, following a prior quarter in which revenue rose strongly year on year but fell short of analyst expectations. The upcoming report is drawing attention because analysts now expect a much slower revenue growth rate, sharpening focus on whether Cadre can sustain its recent expansion pace. We'll examine how the anticipated slowdown in revenue growth and recent estimate miss could...

Event context and recent share performance Enterprise Financial Services (EFSC) has drawn investor attention after recent trading, with the stock down about 1% over the past day, 6% over the past week, and roughly 10% over the past month. Those shorter term moves contrast with a small positive total return over the past year, as well as higher three and five year total returns. This has prompted some investors to reassess how the bank’s current pricing lines up with its fundamentals. See our...

Recently, Halliburton reported quarterly earnings and revenue that exceeded analyst expectations and signed a memorandum of understanding with PT Pertamina to deploy advanced well construction and stimulation technologies in Indonesia. This combination of earnings outperformance and a new Indonesian technology partnership underscores Halliburton’s push to build a broader, more geographically diverse service footprint. We’ll now examine how Halliburton’s Pertamina technology agreement could...

Watts Water Technologies recently reported record fourth-quarter and full-year results, beating analyst expectations on revenue, EBITDA, operating income, and earnings per share, with management crediting its focus on water safety, conservation, and energy efficiency for the strong performance. By leading its water infrastructure peer group in both revenue growth and the size of its earnings beat despite broader industry challenges, Watts reinforced the competitive strength of its...

Disc Medicine stock reacts after recent share price moves Disc Medicine (IRON) has drawn attention after recent share price swings, including a 5.0% gain over the past day, offset by declines over the past week, month, and past 3 months. See our latest analysis for Disc Medicine. The latest 1 day share price gain sits against weaker short term momentum, with the 30 day share price return of 19.43% decline and 90 day share price return of 29.97% decline contrasting with a 1 year total...

Why the PX Q650 launch matters for Energy Recovery (ERII) investors Energy Recovery (ERII) has drawn fresh attention after launching its PX Q650 Pressure Exchanger for desalination, combining higher flow capacity, very high stated efficiency, and extended warranties aimed at long-life plant operations. See our latest analysis for Energy Recovery. The PX Q650 launch comes on the heels of Energy Recovery’s recent earnings update. It arrives at a time when the stock has seen a 4.81% 1 day share...

In late February and early March 2026, Dynatrace drew attention as Executive Vice President Stephen McMahon bought 3,000 company shares for about US$107,250 and the firm highlighted its artificial intelligence-driven observability platform at Morgan Stanley’s Technology, Media & Telecom Conference in San Francisco. This combination of insider buying and a public focus on AI-enabled growth and raised profit guidance adds weight to Dynatrace’s existing growth and innovation story for...

In February 2026, Gilead Sciences presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing its investigational single-tablet bictegravir/lenacapavir HIV regimen maintained virologic suppression and was generally well tolerated, proving noninferior to both complex multi-tablet regimens and guideline-recommended single-tablet therapy through Week 48. This potential new once-daily option could simplify treatment for people living with HIV who are currently on complex regimens, reinforcing...

Hertz Global Holdings, Inc. reported past fourth-quarter 2025 sales of US$2,028 million versus US$2,040 million a year earlier, with its quarterly net loss narrowing to US$194 million from US$479 million; full-year 2025 sales were US$8.50 billion versus US$9.05 billion, while the annual net loss improved to US$747 million from US$2.86 billion. Pershing Square’s 2025 commentary framed Hertz as an emerging comeback story, highlighting a refreshed fleet, higher utilization, and the company’s...

In March 2026, Biohaven Ltd. reported fourth-quarter and full-year 2025 results showing its net loss narrowed to US$145.56 million for the quarter and US$738.82 million for the year, alongside reduced basic loss per share. On the same day, Biohaven also filed a US$134.78 million shelf registration for nearly 11.7 million common shares tied to an employee stock ownership plan, highlighting ongoing efforts to access capital and incentivize staff. We will now examine how Biohaven’s narrower...

T. Rowe Price has appointed Richard Parkin as head of UK retirement, effective 9 March 2026, bringing over 35 years of pensions and retirement experience from roles at BNY Investments, Fidelity International, and key industry bodies. Parkin’s remit to shape the firm’s UK retirement strategy across retail and institutional channels highlights T. Rowe Price’s focus on expanding retirement solutions alongside its growing assets under management and earnings base. Next, we’ll examine how...

IES Holdings recently held its 2026 Annual Stockholders Meeting, where all director nominees were elected and Ernst & Young was ratified as auditor, while Director Todd Cleveland sold 2,500 shares, trimming his personal stake. Together with ongoing attention on the Gulf Island acquisition, these governance developments are sharpening investor focus on how IES allocates capital and manages oversight. Next, we’ll examine how the director’s share sale and refreshed governance framework shape...

Churchill Downs Incorporated has released its fourth-quarter and full-year 2025 results, showing higher revenue of US$665.9 million for the quarter and US$2.93 billion for the year, but lower net income of US$51.3 million and US$383 million respectively compared with the prior year. The company also opened Marshall Yards Racing & Gaming in Calvert City, Kentucky in February 2026, adding its eighth historical horse racing venue in the state and further tying gaming operations to purse funding...

Zevra Therapeutics, Inc. has reported its 2025 results, with full-year sales rising to US$106.47 million and net income reaching US$83.23 million, alongside fourth-quarter revenue of US$34.1 million and adjusted earnings of US$1.16 per share. Alongside these results, Zevra filed a US$22.86 million employee stock offering and named veteran finance executive Justin Renz as its new Chief Financial Officer, underscoring a focus on commercial scale-up and corporate development. We’ll now examine...

Marqeta (MQ) is back in focus after its fourth quarter 2025 update, which paired higher reported sales and a sharply smaller net loss with fresh 2026 guidance on revenue and gross profit growth. See our latest analysis for Marqeta. Marqeta’s earnings update and 2026 guidance have arrived after a softer patch in the stock. The 7 day share price return of 4.88% contrasts with a 90 day share price return of negative 15.35% and a 3 year total shareholder return of negative 3.09%. This suggests...

Occidental Petroleum (OXY) is back in focus after it expanded the size of its cash tender offers to repurchase up to US$1.2b of outstanding notes and secured key bondholder consents. See our latest analysis for Occidental Petroleum. Occidental’s expanded tender offer and strong early bondholder participation come as the share price trades at US$55.02, with a 30 day share price return of 18.81% and year to date share price return of 29.83%. The 5 year total shareholder return of 100.16%...

Recent share performance and what it means for investors Hercules Capital (HTGC) has drawn investor attention after a recent pullback, with the stock showing negative returns over the past month and past 3 months, alongside a weaker move over the past year. At a last close of US$14.67, Hercules Capital sits below its recent levels. Returns of 76.11% over 3 years and 53.64% over 5 years provide a longer term contrast to its shorter term performance. See our latest analysis for Hercules...

What ResMed’s new Greenwood hub could mean for the stock ResMed (RMD) is opening a new distribution center in Greenwood, Indiana, planned to start operations in 2027. The facility is intended to improve delivery coverage and speed for its sleep and respiratory care products across North America. See our latest analysis for ResMed. At a share price of US$252.93, ResMed has had a softer patch recently with a 30 day share price return of a 6.88% decline, even though its 1 year total shareholder...

Why Kymera’s latest update matters for shareholders Kymera Therapeutics (KYMR) has put several big items on the table at once, including a planned US$500 million at the market equity offering, wider quarterly and full year losses, and a new Chief Development Officer. These moves come as the company continues to invest in its protein degradation pipeline, and they raise practical questions for you around dilution, funding flexibility, and how leadership changes might influence the pace and...

Leadership shift and upcoming conference draw attention to Capri Holdings stock The recent decision by Capri Holdings (CPRI) to appoint Tyler Reddien as both Chief Financial Officer and Chief Operating Officer, along with an upcoming appearance at Citi’s 2026 Global Consumer & Retail Conference, has brought fresh attention to the stock. See our latest analysis for Capri Holdings. Capri Holdings' share price has softened over the past year, with a 30 day share price return of a 9.22% decline...

Belite Bio, Inc reported fourth-quarter and full-year 2025 results, with net loss widening to US$25.32 million for the quarter and US$77.61 million for the year, compared with US$10.1 million and US$36.14 million respectively in the prior periods. The company is now absorbing materially higher per-share losses as it scales R&D and commercial infrastructure ahead of potential Tinlarebant approvals in rare retinal diseases. We’ll now examine how Belite Bio’s significantly wider 2025 net loss...